Emergent BioSolutions Inc. Common Stock (EBS)

Competitors to Emergent BioSolutions Inc. Common Stock (EBS)

AstraZeneca plc

AstraZeneca plc is a leading biopharmaceutical company with a diversified portfolio that includes vaccines. Both AstraZeneca and Emergent BioSolutions target similar markets in infectious disease, particularly highlighted during the COVID-19 pandemic. AstraZeneca's significant resources, established global market presence, and extensive partnerships allow it to excel in research and product delivery, thus providing it a competitive edge over Emergent BioSolutions.

CSL Limited

CSL Limited is a global biotechnology company that develops innovative biotherapies, including vaccines and other immunotherapies, similar to Emergent BioSolutions' product lines. CSL has a strong presence in the plasma-derived therapies sector and a robust pipeline, which gives it a competitive edge. Its established global network and experience in large-scale production and distribution provide it with a significant advantage in gaining contracts and market share compared to Emergent BioSolutions.

Novavax, Inc. 

Novavax, Inc. specializes in developing vaccines and has been prominent in the COVID-19 vaccine race, sharing similarities with Emergent BioSolutions in terms of their focus on public health solutions. While both companies have received government contracts for vaccine development, Novavax's recent advancements and partnerships, along with its strong funding backed by governmental and global health organizations, provide it with a competitive advantage in the vaccine development space.

Pfizer Inc. 

Pfizer Inc. is one of the largest pharmaceutical companies in the world and, like Emergent BioSolutions, is involved in vaccine development and biopharmaceuticals. Both companies have contributed to the COVID-19 vaccination efforts, but Pfizer’s vast resources, strong market presence, and extensive pipeline of products provide it a notable advantage in scaling and delivering vaccines efficiently. This stronghold makes Pfizer a formidable competitor in the biopharmaceutical industry.

Valneva SE 

Valneva SE focuses on developing and commercializing vaccines that address unmet medical needs, similar to Emergent BioSolutions' vaccine portfolio. Both companies have invested heavily in vaccine research and development, particularly in infectious diseases. However, Valneva has a competitive advantage through its innovative approach to vaccine technology and its pipeline of candidates for diseases such as Lyme disease and chikungunya, which may provide them with opportunities in niche markets.